Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.3K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A sentiment analysis and topic modeling of weibo discourse on public perceptions of breast cancer.

Digital health·2026
Same author

Functional Characterization and Application of Autochthonous Lactic Acid Bacteria from Chinese Kefir for Improved Fermented Milk Quality.

Journal of dairy science·2026
Same author

Aquatic ecosystem degradation attributed to tire wear particles in urban roadway runoff.

Environmental pollution (Barking, Essex : 1987)·2026
Same author

Co-exposure to environmental lead and hypertension exacerbates anxiety and depression via mtDNA-mediated cGAS phase separation.

Environmental pollution (Barking, Essex : 1987)·2026
Same author

Drying methods for <i>Rheum tanguticum</i>: a comprehensive study of quality traits and metabolite dynamics.

Frontiers in pharmacology·2026
Same author

Nanopore Polyphenol Fingerprinting with Anthocyanin-Catechin Signatures for Tea Quality Grading and Cultivar Discrimination.

Nano letters·2026

Related Experiment Video

Updated: Apr 4, 2026

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

2.0K

Dynamic T-Cell Reprogramming Modulates the Treatment Outcome of Neoadjuvant Immunochemotherapy in Non-Small-Cell Lung

Rui Jin1, Anhao Tian2, Weina Lu1,3

  • 1Key Laboratory of Respiratory Disease of Zhejiang Province Department of Respiratory and Critical Care Medicine Second Affiliated Hospital of Zhejiang University School of Medicine Hangzhou Zhejiang China.

Medcomm
|April 3, 2026
PubMed
Summary
This summary is machine-generated.

Neoadjuvant chemoimmunotherapy shows promise for non-small-cell lung cancer (NSCLC), but many patients still do not respond. This study reveals bidirectional T-cell dynamics, involving CD8+ T cells and regulatory T cells (Tregs), that influence patient responses to treatment.

Keywords:
T cellimmunochemotherapyneoadjuvantnon‐small‐cell lung cancer (NSCLC)

More Related Videos

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

1.9K
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

4.2K

Related Experiment Videos

Last Updated: Apr 4, 2026

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

2.0K
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

1.9K
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

4.2K

Area of Science:

  • Immunology
  • Oncology
  • Genomics

Background:

  • Neoadjuvant chemoimmunotherapy is a developing strategy for non-small-cell lung cancer (NSCLC).
  • A significant proportion of NSCLC patients exhibit poor responses to perioperative chemoimmunotherapy, necessitating deeper mechanistic understanding.
  • Investigating T-cell dynamics within the tumor microenvironment is crucial for improving treatment outcomes.

Purpose of the Study:

  • To characterize dynamic T-cell changes in response to neoadjuvant chemoimmunotherapy in NSCLC.
  • To elucidate the mechanisms underlying pathological response and non-response in NSCLC patients.
  • To identify specific T-cell subsets and their roles in treatment efficacy.

Main Methods:

  • Single-cell RNA sequencing and T-cell receptor (TCR) sequencing were performed on paired pre- and post-treatment samples.
  • Analysis focused on nine NSCLC patients with varying pathological responses.
  • T-cell subsets, TCR clonality, and diversity were assessed to understand dynamic changes.

Main Results:

  • Bi-directional T-cell mechanisms were identified correlating with pathological responsiveness.
  • Responders showed increased TCR clonality and diversity in CD8+ T-cell subsets (Tem, Teff, Trm, Tex), with CD8+ Tem cells being particularly significant.
  • Non-responders exhibited increased novel clonal expansion and enhanced functional profiles in inhibitory regulatory T cells (Tregs).

Conclusions:

  • T-cell dynamics play a bidirectional role in the response to neoadjuvant chemoimmunotherapy in NSCLC.
  • Understanding these T-cell dynamics, including CD8+ T-cell subsets and Tregs, offers insights into treatment response mechanisms.
  • These findings can guide strategies to improve prognoses for NSCLC patients undergoing neoadjuvant chemoimmunotherapy.